Iqbal Haroon, Razzaq Anam, Yuan Ziyin, Zhai Lina, Wang Yue, Ur-Rehman Uzair, Man Lv, Xin Jun, Ning Xin, Liang Yuanbo, Xiao Run
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Eye Research Center, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Eye Hospital, Wenzhou Medical University, Hangzhou, 310018, China.
Biomater Res. 2025 Sep 3;29:0245. doi: 10.34133/bmr.0245. eCollection 2025.
Cancer is a devastating disease, and its pathogenesis is highly associated with malnutrition and poor lifestyle. Chemotherapy continuously causes inadequate therapeutic efficacy and induces off-target toxicities. Hence, targeted co-administration of chemotherapy and dietary supplement producing anticancer effect at low doses with minimized toxicities would be a promising strategy for cancer treatment. In this study, we constructed chondroitin sulfate (CS) and methotrexate (MTX) carried serum albumin nanocages (C/M@Alb NCs) by albumin nanoreactor strategy. During fabrication, we achieved the precipitation of MTX and CS inside the albumin nanocore under mild reaction condition to prepare C/M@Alb NCs. The enhanced anticancer efficacy of C/M@Alb NCs was comprehensively assessed by in vitro and in vivo experiments. Biodistribution, pharmacokinetic profile, and in vivo therapeutic efficacy of C/M@Alb NCs were investigated in human colorectal adenocarcinoma (HT-29), murine breast cancer (E0071), and patient-derived (PDX) lung cancer models. The as-prepared C/M@Alb NCs facilitated higher MTX and CS encapsulation, exhibiting small particle size, improved colloidal stability, dual stimuli (pH/GSH)-responsive drug release profile, an enhanced cellular uptake, cooperative synergistic cytotoxicity, extended blood residence time, improved lymph node and tumor targeting, and in vivo therapeutic efficacy against various cancers such as human colorectal adenocarcinoma, murine breast cancer, and patient-derived (PDX) lung cancer. Altogether, C/M@Alb NCs exhibited enhanced cellular uptake, extended blood residence time, and favorable tumor accumulation and lymph node extravasation, finally leading to the potent antitumor efficacy against various cancers. This nanoplatform offers a new strategy for designing lymph node- and cancer-targeted albumin-based nanomedicine for clinical applications.
癌症是一种毁灭性疾病,其发病机制与营养不良和不良生活方式高度相关。化疗持续导致治疗效果不佳,并引发脱靶毒性。因此,以低剂量联合使用化疗药物和膳食补充剂,在产生抗癌效果的同时将毒性降至最低,将是一种很有前景的癌症治疗策略。在本研究中,我们通过白蛋白纳米反应器策略构建了负载硫酸软骨素(CS)和甲氨蝶呤(MTX)的血清白蛋白纳米笼(C/M@Alb NCs)。在制备过程中,我们在温和的反应条件下实现了MTX和CS在白蛋白纳米核内的沉淀,以制备C/M@Alb NCs。通过体外和体内实验全面评估了C/M@Alb NCs增强的抗癌效果。在人结肠腺癌(HT-29)、小鼠乳腺癌(E0071)和患者来源的(PDX)肺癌模型中研究了C/M@Alb NCs的生物分布、药代动力学特征和体内治疗效果。所制备的C/M@Alb NCs促进了更高的MTX和CS包封率,呈现出小粒径、改善的胶体稳定性、双刺激(pH/GSH)响应性药物释放曲线、增强的细胞摄取、协同增效的细胞毒性、延长的血液滞留时间、改善的淋巴结和肿瘤靶向性以及对人结肠腺癌、小鼠乳腺癌和患者来源的(PDX)肺癌等多种癌症的体内治疗效果。总之,C/M@Alb NCs表现出增强的细胞摄取、延长的血液滞留时间以及良好的肿瘤蓄积和淋巴结外渗,最终导致对多种癌症的强效抗肿瘤疗效。这种纳米平台为设计用于临床应用的淋巴结和癌症靶向白蛋白基纳米药物提供了一种新策略。